Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease

Juliane Totzke, Deepak Gurbani, Rene Raphemot, Philip F. Hughes, Khaldon Bodoor, David A. Carlson, David R. Loiselle, Asim K. Bera, Liesl S. Eibschutz, Marisha M. Perkins, Amber L. Eubanks, Phillip L. Campbell, David A. Fox, Kenneth D. Westover, Timothy A.J. Haystead, Emily R. Derbyshire

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Tumor necrosis factor alpha (TNF-α) has both positive and negative roles in human disease. In certain cancers, TNF-α is infused locally to promote tumor regression, but dose-limiting inflammatory effects limit broader utility. In autoimmune disease, anti-TNF-α antibodies control inflammation in most patients, but these benefits are offset during chronic treatment. TAK1 acts as a key mediator between survival and cell death in TNF-α-mediated signaling. Here, we describe Takinib, a potent and selective TAK1 inhibitor that induces apoptosis following TNF-α stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. We demonstrate that Takinib is an inhibitor of autophosphorylated and non-phosphorylated TAK1 that binds within the ATP-binding pocket and inhibits by slowing down the rate-limiting step of TAK1 activation. Overall, Takinib is an attractive starting point for the development of inhibitors that sensitize cells to TNF-α-induced cell death, with general implications for cancer and autoimmune disease treatment.

Original languageEnglish (US)
Pages (from-to)1029-1039.e7
JournalCell Chemical Biology
Volume24
Issue number8
DOIs
StatePublished - Aug 17 2017

Fingerprint

Autoimmune Diseases
Tumor Necrosis Factor-alpha
Neoplasms
Cell death
Cell Death
Therapeutics
Tumors
Rheumatoid Arthritis
Adenosine Triphosphate
Chemical activation
Apoptosis
Breast Neoplasms
Inflammation
Survival
Antibodies

Keywords

  • autoimmune disease
  • cancer
  • drug discovery
  • enzyme kinetics
  • inflammatory disorders
  • kinase inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Drug Discovery
  • Pharmacology

Cite this

Totzke, J., Gurbani, D., Raphemot, R., Hughes, P. F., Bodoor, K., Carlson, D. A., ... Derbyshire, E. R. (2017). Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chemical Biology, 24(8), 1029-1039.e7. https://doi.org/10.1016/j.chembiol.2017.07.011

Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. / Totzke, Juliane; Gurbani, Deepak; Raphemot, Rene; Hughes, Philip F.; Bodoor, Khaldon; Carlson, David A.; Loiselle, David R.; Bera, Asim K.; Eibschutz, Liesl S.; Perkins, Marisha M.; Eubanks, Amber L.; Campbell, Phillip L.; Fox, David A.; Westover, Kenneth D.; Haystead, Timothy A.J.; Derbyshire, Emily R.

In: Cell Chemical Biology, Vol. 24, No. 8, 17.08.2017, p. 1029-1039.e7.

Research output: Contribution to journalArticle

Totzke, J, Gurbani, D, Raphemot, R, Hughes, PF, Bodoor, K, Carlson, DA, Loiselle, DR, Bera, AK, Eibschutz, LS, Perkins, MM, Eubanks, AL, Campbell, PL, Fox, DA, Westover, KD, Haystead, TAJ & Derbyshire, ER 2017, 'Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease', Cell Chemical Biology, vol. 24, no. 8, pp. 1029-1039.e7. https://doi.org/10.1016/j.chembiol.2017.07.011
Totzke, Juliane ; Gurbani, Deepak ; Raphemot, Rene ; Hughes, Philip F. ; Bodoor, Khaldon ; Carlson, David A. ; Loiselle, David R. ; Bera, Asim K. ; Eibschutz, Liesl S. ; Perkins, Marisha M. ; Eubanks, Amber L. ; Campbell, Phillip L. ; Fox, David A. ; Westover, Kenneth D. ; Haystead, Timothy A.J. ; Derbyshire, Emily R. / Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. In: Cell Chemical Biology. 2017 ; Vol. 24, No. 8. pp. 1029-1039.e7.
@article{de0a5f0883564f07995416915675f84a,
title = "Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease",
abstract = "Tumor necrosis factor alpha (TNF-α) has both positive and negative roles in human disease. In certain cancers, TNF-α is infused locally to promote tumor regression, but dose-limiting inflammatory effects limit broader utility. In autoimmune disease, anti-TNF-α antibodies control inflammation in most patients, but these benefits are offset during chronic treatment. TAK1 acts as a key mediator between survival and cell death in TNF-α-mediated signaling. Here, we describe Takinib, a potent and selective TAK1 inhibitor that induces apoptosis following TNF-α stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. We demonstrate that Takinib is an inhibitor of autophosphorylated and non-phosphorylated TAK1 that binds within the ATP-binding pocket and inhibits by slowing down the rate-limiting step of TAK1 activation. Overall, Takinib is an attractive starting point for the development of inhibitors that sensitize cells to TNF-α-induced cell death, with general implications for cancer and autoimmune disease treatment.",
keywords = "autoimmune disease, cancer, drug discovery, enzyme kinetics, inflammatory disorders, kinase inhibitors",
author = "Juliane Totzke and Deepak Gurbani and Rene Raphemot and Hughes, {Philip F.} and Khaldon Bodoor and Carlson, {David A.} and Loiselle, {David R.} and Bera, {Asim K.} and Eibschutz, {Liesl S.} and Perkins, {Marisha M.} and Eubanks, {Amber L.} and Campbell, {Phillip L.} and Fox, {David A.} and Westover, {Kenneth D.} and Haystead, {Timothy A.J.} and Derbyshire, {Emily R.}",
year = "2017",
month = "8",
day = "17",
doi = "10.1016/j.chembiol.2017.07.011",
language = "English (US)",
volume = "24",
pages = "1029--1039.e7",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease

AU - Totzke, Juliane

AU - Gurbani, Deepak

AU - Raphemot, Rene

AU - Hughes, Philip F.

AU - Bodoor, Khaldon

AU - Carlson, David A.

AU - Loiselle, David R.

AU - Bera, Asim K.

AU - Eibschutz, Liesl S.

AU - Perkins, Marisha M.

AU - Eubanks, Amber L.

AU - Campbell, Phillip L.

AU - Fox, David A.

AU - Westover, Kenneth D.

AU - Haystead, Timothy A.J.

AU - Derbyshire, Emily R.

PY - 2017/8/17

Y1 - 2017/8/17

N2 - Tumor necrosis factor alpha (TNF-α) has both positive and negative roles in human disease. In certain cancers, TNF-α is infused locally to promote tumor regression, but dose-limiting inflammatory effects limit broader utility. In autoimmune disease, anti-TNF-α antibodies control inflammation in most patients, but these benefits are offset during chronic treatment. TAK1 acts as a key mediator between survival and cell death in TNF-α-mediated signaling. Here, we describe Takinib, a potent and selective TAK1 inhibitor that induces apoptosis following TNF-α stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. We demonstrate that Takinib is an inhibitor of autophosphorylated and non-phosphorylated TAK1 that binds within the ATP-binding pocket and inhibits by slowing down the rate-limiting step of TAK1 activation. Overall, Takinib is an attractive starting point for the development of inhibitors that sensitize cells to TNF-α-induced cell death, with general implications for cancer and autoimmune disease treatment.

AB - Tumor necrosis factor alpha (TNF-α) has both positive and negative roles in human disease. In certain cancers, TNF-α is infused locally to promote tumor regression, but dose-limiting inflammatory effects limit broader utility. In autoimmune disease, anti-TNF-α antibodies control inflammation in most patients, but these benefits are offset during chronic treatment. TAK1 acts as a key mediator between survival and cell death in TNF-α-mediated signaling. Here, we describe Takinib, a potent and selective TAK1 inhibitor that induces apoptosis following TNF-α stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. We demonstrate that Takinib is an inhibitor of autophosphorylated and non-phosphorylated TAK1 that binds within the ATP-binding pocket and inhibits by slowing down the rate-limiting step of TAK1 activation. Overall, Takinib is an attractive starting point for the development of inhibitors that sensitize cells to TNF-α-induced cell death, with general implications for cancer and autoimmune disease treatment.

KW - autoimmune disease

KW - cancer

KW - drug discovery

KW - enzyme kinetics

KW - inflammatory disorders

KW - kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85027494739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027494739&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2017.07.011

DO - 10.1016/j.chembiol.2017.07.011

M3 - Article

VL - 24

SP - 1029-1039.e7

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 8

ER -